Hypochondroplasia Clinical Trials

20 clinical trials for Hypochondroplasia across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• An Interventional Study of Infigratinib in Children With Hypochondroplasia — RECRUITING · PHASE2
• Prospective Clinical Assessment Study in Children With Hypochondroplasia — RECRUITING
• Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia — RECRUITING · PHASE2
• A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months — RECRUITING · PHASE2
• Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia — RECRUITING
• PHASE 2, OPEN-LABEL, LONG-TERM, EXTENSION (OLE) STUDY OF INFIGRATINIB, AN FGFR 1-3-SELECTIVE TYROSINE KINASE INHIBITOR, IN CHILDREN WITH HYPOCHONDROPLASIA: ACCEL OLE — RECRUITING · PHASE2
• Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia — RECRUITING · PHASE3
• A PHASE 3, OPEN-LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VOSORITIDE IN CHILDREN WITH HYPOCHONDROPLASIA — RECRUITING · PHASE3
• A Multicenter Multinational Observational Study of Children With Hypochondroplasia — RECRUITING
• A PHASE 2/3, MULTICENTER, OPEN-LABEL PHASE FOLLOWED BY A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INFIGRATINIB IN CHILDREN WITH HYPOCHONDROPLASIA: ACCEL 2/3 — RECRUITING · PHASE2
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VOSORITIDE IN CHILDREN WITH HYPOCHONDROPLASIA. — RECRUITING · PHASE3
• Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy) — RECRUITING
• A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children with Hypochondroplasia — TERMINATED · PHASE3
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children with Hypochondroplasia, Aged 0 to < 36 Months — TERMINATED · PHASE2
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children with Hypochondroplasia — OTHER · PHASE3
• Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE — TERMINATED · PHASE2
• A Phase 2/3, Multicenter, Open-Label Phase Followed by a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children with Hypochondroplasia: ACCEL 2/3 — TERMINATED · PHASE3
• Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia — ACTIVE_NOT_RECRUITING · PHASE3
• Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children — COMPLETED · PHASE2
• C-Type Natriuretic Peptide and Achondroplasia — COMPLETED

Refine this search